Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

26.48 -5.70 (-17.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
33 34 Next >
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
From Cassava Sciences, Inc.
Via GlobeNewswire
7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022
After getting knocked down by controversy this year, can any of these seven corporate scandal stocks make a recovery? 
Via InvestorPlace
$100 Invested In Cassava Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Up Today?
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Cassava Sciences: Q3 Earnings Insights
Cassava Sciences (NASDAQ:SAVA) reported its Q3 earnings results on Monday, November 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
Is the Stock Market Open on Election Day 2022?
Investors are wondering if the stock market is open on Election Day this year as they seek out extra time to head to the polls! 
Via InvestorPlace
Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers
SAVA stock is in the green after reporting earnings. The company also filed a lawsuit against short sellers, alleging misleading statements. 
Via InvestorPlace
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
What the Latest Controversy Really Means for SAVA Stock
SAVA stock continues to be dogged by controversy, but the risk/reward proposition for this biotech largely remains the same. 
Via InvestorPlace
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
From Cassava Sciences, Inc.
Via GlobeNewswire
Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
SAVA stock is in the red after a piece from Probes Reporter accused Cassava of being involved with two undisclosed SEC investigations. 
Via InvestorPlace
A New Study Makes Cassava Sciences Stock an Interesting Buy
With the biotech firm moving forward with an open-label study of its Alzheimer's treatment simufilam, SAVA stock is one to watch. 
Via InvestorPlace
Cassava Sciences Announces Expansion of Leadership Team
From Cassava Sciences, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
SAVA Stock Alert: Cassava Sciences Extends Trial
SAVA stock is in focus after Cassava announced that it would begin an open-label study of its investigational Alzheimer's drug, simufilam. 
Via InvestorPlace
Cassava Sciences Announces Initiation of an Open-label Extension Study
From Cassava Sciences, Inc.
Via GlobeNewswire
Don’t Let Misconduct Allegations Cloud Your Perception of SAVA Stock
It's easy to get mired in the controversy surrounding Cassava Sciences, but distracted SAVA stock traders might miss an opportunity. 
Via InvestorPlace
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates 
Via MarketBeat
Exposures Product Safety
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
Via Benzinga
2 Signals to Watch Before Buying SAVA Stock
SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play. 
Via InvestorPlace
EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
$100 Invested In Cassava Sciences 15 Years Ago Would Be Worth This Much Today
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 15 years by 3.29% on an annualized basis producing an average annual return of 9.08%. Currently, Cassava Sciences has a market... 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 20 years by 4.23% on an annualized basis producing an average annual return of 12.02%. Currently, Cassava Sciences has a market... 
Via Benzinga
How High Can SAVA Stock Go Once the Controversy Clears?
If a reproduced SEC letter concerning Cassava Sciences' clearance is legit, SAVA stock could head much higher. 
Via InvestorPlace
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.